Want to see IN:ZIMLAB full AI Analyst Report?
Top Page
Zim Laboratories Ltd.
(ZIMLAB)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹138.00
▲(94.07% Upside)
Action:Reiterated
Date:08/21/26
The score is held back primarily by weakening profitability and volatile/negative free cash flow, despite a reasonably supported balance sheet. Technicals are moderately constructive with price above key moving averages, but the very high P/E reduces attractiveness on valuation.
Positive Factors
Supported balance sheet
Rising equity provides a stronger capital base for product development, manufacturing investment, and working-capital needs. Moderate leverage also preserves financial flexibility, helping the company support operations and pursue growth without relying excessively on additional borrowing.
Negative Factors
Sharp earnings deterioration
The sharp decline in net income signals that recent revenue has not translated into durable earnings growth. Lower operating profit and reduced efficiency can constrain reinvestment, weaken returns on capital, and make future earnings more sensitive to execution and product mix.
Read all positive and negative factors
Positive Factors
Negative Factors
Supported balance sheet
Rising equity provides a stronger capital base for product development, manufacturing investment, and working-capital needs. Moderate leverage also preserves financial flexibility, helping the company support operations and pursue growth without relying excessively on additional borrowing.
Read all positive factors
Zim Laboratories Ltd. (ZIMLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹7.32B
Dividend Yield0.15%
Average Volume (3M)9.60K
Price to Earnings (P/E)168.3
Beta (1Y)1.07
Revenue Growth7.55%
EPS Growth-57.19%
CountryIN
Employees632
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.82
Shares Outstanding53,658,490
10 Day Avg. Volume8,894
30 Day Avg. Volume9,598
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)1.00
Price to Sales (P/S)0.80
P/FCF Ratio-39.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zim Laboratories Ltd. Business Overview & Revenue Model
Company Description
Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally,...
How the Company Makes Money
Zim Laboratories primarily makes money by selling pharmaceutical formulations (finished dosage-form medicines). Key revenue streams typically include: (1) sales of its own branded/generic products in domestic and/or export markets through distribu...
Zim Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
66
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.97B | 3.69B | 3.74B | 3.68B | 3.99B | 3.31B |
| Gross Profit | 1.33B | 616.36M | 730.04M | 1.86B | 903.81M | 1.67B |
| EBITDA | 302.45M | 256.46M | 495.11M | 454.76M | 582.00M | 452.62M |
| Net Income | 36.96M | 58.38M | 121.65M | 172.46M | 244.34M | 145.50M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.39B | 4.72B | 4.47B | 3.42B | 3.42B |
| Cash, Cash Equivalents and Short-Term Investments | 402.52M | 278.02M | 20.37M | 96.41M | 64.66M | 34.20M |
| Total Debt | 0.00 | 1.26B | 1.18B | 1.12B | 620.00M | 533.14M |
| Total Liabilities | -2.96B | 2.43B | 2.20B | 2.08B | 1.41B | 1.66B |
| Stockholders Equity | 2.96B | 2.96B | 2.52B | 2.39B | 2.00B | 1.76B |
Cash Flow | ||||||
| Free Cash Flow | 40.45M | -75.72M | 3.57M | -576.45M | 15.00M | 339.81M |
| Operating Cash Flow | 199.18M | 368.15M | 411.55M | 162.78M | 381.68M | 492.06M |
| Investing Cash Flow | -155.70M | -565.23M | -399.27M | -730.13M | -362.04M | -145.71M |
| Financing Cash Flow | -34.19M | 410.81M | -91.05M | 595.34M | 5.46M | -329.70M |
Zim Laboratories Ltd. Technical Analysis
Positive
71.11
Price Trends
124.18
Positive
118.30
Positive
95.91
Positive
Market Momentum
3.51
Positive
56.57
Neutral
39.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZIMLAB, the sentiment is Positive. The current price of 71.11 is below the 20-day moving average (MA) of 134.49, below the 50-day MA of 124.18, and below the 200-day MA of 95.91, indicating a bullish trend. The MACD of 3.51 indicates Positive momentum. The RSI at 56.57 is Neutral, neither overbought nor oversold. The STOCH value of 39.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ZIMLAB.
Zim Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ₹7.55B | 24.93 | ― | 0.40% | 14.04% | 2.57% | |
61 Neutral | ₹9.11B | 115.12 | ― | 1.93% | -3.14% | -5.80% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹4.86B | 21.53 | ― | 0.58% | 11.43% | 258.53% | |
52 Neutral | ₹1.83B | 13.17 | ― | ― | 49.96% | 33.70% | |
50 Neutral | ₹6.63B | 41.90 | ― | ― | 89.64% | 10627.64% | |
50 Neutral | ₹7.32B | 168.29 | ― | 0.15% | 7.55% | -57.19% |
* General Sector Average
IN:ZIMLAB
Zim Laboratories Ltd.
136.45
65.04
91.08%
IN:ALBERTDAVD
Albert David Ltd
851.10
67.30
8.59%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
385.00
214.00
125.15%
IN:KILITCH
Kilitch Drugs (India) Limited
216.05
30.60
16.50%
IN:MEDICO
Medico Remedies Ltd.
22.00
-28.73
-56.63%
IN:VALIANTLAB
Valiant Laboratories Ltd.
122.10
39.82
48.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.